Prostaglandin E2 Inhibition and Aqueous Concentration of Ketorolac 0.4% (Acular LS) and Nepafenac 0.1% (Nevanac) in Patients Undergoing Phacoemulsification  

Oleh:

Bucci, Frank A ; Waterbury, L. David ; Amico, Loretta M

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: American Journal of Ophthalmology (keterangan: ada di ClinicalKey) vol. 144 no. 01 (Jul. 2007), page 146.

Ketersediaan

Perpustakaan FK Nomor Panggil: A12.K.2007.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Purpose To determine the prostaglandin E2 (PGE2) levels and aqueous concentrations achieved with ketorolac 0.4% (Acular LS; Allergan, Inc, Irvine, California, USA) and nepafenac 0.1% (Nevanac; Alcon Laboratories, Inc, Fort Worth, Texas, USA). Design Single-center, randomized, double-masked study. Methods One hundred and thirty-two patients received ketorolac or nepafenac four times daily for two days before cataract extraction. Aqueous samples obtained at surgery were analyzed for PGE2 levels (competitive enzyme immunoassay) and drug concentrations. Results More ketorolac eyes than nepafenac eyes had PGE2 levels less than the level of detection (<100 pg/ml; 26/42 [61.9%] and 7/40 [17.5%], respectively; P < .001). Mean PGE2 levels in ketorolac eyes were lower than that in nepafenac eyes (159.5 ± 114.66 pg/ml and 322 ± 197.8 pg/ml, respectively; P < .001). The mean aqueous level was 1079.1 ± 881.5 ng/ml with ketorolac and 353.4 ± 126.0 ng/ml with amfenac. The nepafenac eyes exhibited 588.4 ± 394.6 ng/ml of the inactive nepafenac molecule (P < .001 vs ketorolac). Conclusions Ketorolac 0.4% inhibited PGE2 and penetrated into aqueous significantly more than nepafenac 0.1%.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali